Compare CVE & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVE | ONC |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 34.8B |
| IPO Year | N/A | N/A |
| Metric | CVE | ONC |
|---|---|---|
| Price | $15.84 | $334.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $26.00 | ★ $369.50 |
| AVG Volume (30 Days) | ★ 11.1M | 261.5K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.23 | 0.58 |
| Revenue | ★ $37,063,946,178.00 | $4,972,687,000.00 |
| Revenue This Year | N/A | $895.40 |
| Revenue Next Year | N/A | $22.04 |
| P/E Ratio | ★ $13.19 | $547.88 |
| Revenue Growth | N/A | ★ 50.43 |
| 52 Week Low | $10.23 | $172.67 |
| 52 Week High | $18.75 | $385.22 |
| Indicator | CVE | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 60.11 |
| Support Level | $15.81 | $302.14 |
| Resistance Level | $17.59 | $310.88 |
| Average True Range (ATR) | 0.43 | 6.86 |
| MACD | -0.08 | 2.66 |
| Stochastic Oscillator | 12.01 | 92.34 |
Cenovus Energy Inc is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 786 thousand barrels of oil equivalent per day in 2022. The company had upstream projects across Western Canada; crude oil production and natural gas and NGLs production offshore China and Indonesia. The downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.